GenSight Submits Lumevoq® Dossier to ANSM for Early Access Program Restart
GenSight Biologics has submitted an updated regulatory file for its LUMEVOQ® gene therapy to the French medicines safety agency...
Carmat’s Aeson® Artificial Heart Revolutionizes Transplants in Europe
CARMAT’s Aeson® artificial heart has seen increased adoption as a European bridge-to-transplant solution. By the end of October 2024,...
How GDPR Drives Trust in Patient-Centric Trials
In recent years, patient-centric trial designs have emerged as a transformative approach in clinical research, placing patients at the...
Quince Therapeutics Unveils Promising Attest Trial Safety Data at CNS Meeting
Quince Therapeutics, a late-stage biotechnology company, announced safety data from its Phase 3 ATTeST clinical trial at the 53rd...
Neurogene Reports Positive Interim Data from NGN-401 Gene Therapy Clinical Trial for Rett Syndrome
Neurogene Inc. announced positive interim clinical data from its Phase 1/2 open-label trial of NGN-401 gene therapy for Rett...
AI and ML in Drug Development – A Deep Dive at DPHARM
The DPHARM conference brought together a panel of experts to discuss the transformative potential of Artificial Intelligence (AI) and...
Novartis Presents New Clinical Trial ALS Digital Health Biomarkers
At Panagora’s 7th Annual Digital Biomarkers in Clinical Trials Summit, Novartis presented a groundbreaking study on digital home-based assessments...
Tezspire Meets Co-primary Endpoints in Phase 3 WAYPOINT Trial
A Phase III trial, WAYPOINT, has yielded positive results for AstraZeneca and Amgen’s TEZSPIRE (tezepelumab) in treating chronic rhinosinusitis...
AI in Biopharmaceutical R&D: From Theory to Practice
At a recent conference, industry leaders gathered to explore the transformative potential of artificial intelligence (AI) in clinical trials,...
Alzheimer’s Trials and Others See More Diversity When Technology and Humans Work Together
Clinical trial sponsors are facing mounting pressure to secure trial participants that more closely reflect the diverse populations affected...